Author Interviews, Gastrointestinal Disease, Pediatrics, Personalized Medicine / 26.09.2019
Precision Medicine: Genetic Variants Predict Response of Eosinophilic Esophagitis to PPIs
MedicalResearch.com Interview with:
[caption id="attachment_51656" align="alignleft" width="151"]
Dr. Franciosi[/caption]
James P. Franciosi, MD
Chief of Gastroenterology, Hepatology and Nutrition
Nemours Children's Hospital
MedicalResearch.com: What is the background for this study?
Response: Eosinophilic Esophagitis (EoE) is a chronic inflammation of the esophagus that is driven by eosinophils. A common class of medications used for this condition are called Proton Pump Inhibitors, or PPIs, which block the production of gastric acid in the stomach. Currently only 30 to 60 percent of children with EoE respond well when treated with PPIs.
We hypothesized that genetic variants in the genes for CYP2C19 and STAT6 could plausibly be associated with response to PPI therapy for EoE.
Dr. Franciosi[/caption]
James P. Franciosi, MD
Chief of Gastroenterology, Hepatology and Nutrition
Nemours Children's Hospital
MedicalResearch.com: What is the background for this study?
Response: Eosinophilic Esophagitis (EoE) is a chronic inflammation of the esophagus that is driven by eosinophils. A common class of medications used for this condition are called Proton Pump Inhibitors, or PPIs, which block the production of gastric acid in the stomach. Currently only 30 to 60 percent of children with EoE respond well when treated with PPIs.
We hypothesized that genetic variants in the genes for CYP2C19 and STAT6 could plausibly be associated with response to PPI therapy for EoE.
